OBJECTIVE: To identify clinical and sociodemographic characteristics associated with suicidal ideation (SI) among patients seeking care for depression in routine primary and psychiatric care settings. METHODS: We examined data from 4041 treatment-seeking outpatients with major depressive disorder (MDD) to compare baseline sociodemographic and clinical characteristics of those with and without SI, and the presence or absence of baseline depressive symptoms and psychiatric comorbidities in those with SI. RESULTS:SI was significantly (P < 0.01) associated with numerous sociodemographic characteristics (that is, lower level of education, Caucasian or African American, male, unemployed, and treated in psychiatric care) and clinical features (that is, previous suicide attempt, younger age of MDD onset, greater baseline depressive symptom severity, greater number of depressive symptoms, and presence of agoraphobia and [or] generalized anxiety disorder). Elevated levels of SI at baseline were associated with decreased remission rates. CONCLUSIONS: Consistent with past findings, increased rates of SI were associated with greater depressive symptom severity as well as other features suggestive of severity of illness. Our results confirm previous findings of associations between SI and panic and (or) phobic symptoms and anxiety, but did not confirm previous findings of an association between SI and alcohol or drug use and (or) dependence. While selective serotonin reuptake inhibitor monotherapy appeared significantly helpful in reducing SI during the course of treatment, the presence of SI at baseline was found to be a associated with decreased treatment response, with patients reporting SI at the start of treatment being less likely to achieve remission. CLINICAL TRIAL REGISTRATION NUMBER: Sequenced Treatment Alternatives to Relieve Depression, NCT00021528.
RCT Entities:
OBJECTIVE: To identify clinical and sociodemographic characteristics associated with suicidal ideation (SI) among patients seeking care for depression in routine primary and psychiatric care settings. METHODS: We examined data from 4041 treatment-seeking outpatients with major depressive disorder (MDD) to compare baseline sociodemographic and clinical characteristics of those with and without SI, and the presence or absence of baseline depressive symptoms and psychiatric comorbidities in those with SI. RESULTS: SI was significantly (P < 0.01) associated with numerous sociodemographic characteristics (that is, lower level of education, Caucasian or African American, male, unemployed, and treated in psychiatric care) and clinical features (that is, previous suicide attempt, younger age of MDD onset, greater baseline depressive symptom severity, greater number of depressive symptoms, and presence of agoraphobia and [or] generalized anxiety disorder). Elevated levels of SI at baseline were associated with decreased remission rates. CONCLUSIONS: Consistent with past findings, increased rates of SI were associated with greater depressive symptom severity as well as other features suggestive of severity of illness. Our results confirm previous findings of associations between SI and panic and (or) phobic symptoms and anxiety, but did not confirm previous findings of an association between SI and alcohol or drug use and (or) dependence. While selective serotonin reuptake inhibitor monotherapy appeared significantly helpful in reducing SI during the course of treatment, the presence of SI at baseline was found to be a associated with decreased treatment response, with patients reporting SI at the start of treatment being less likely to achieve remission. CLINICAL TRIAL REGISTRATION NUMBER: Sequenced Treatment Alternatives to Relieve Depression, NCT00021528.
Authors: Christa D Labouliere; Prabu Vasan; Anni Kramer; Greg Brown; Kelly Green; Mahfuza Rahman; Jamie Kammer; Molly Finnerty; Barbara Stanley Journal: Suicidologi Date: 2018
Authors: Bartholt Bloomfield-Clagett; Dede K Greenstein; Joseph M Kush; Rashelle Musci; Carlos A Zarate; Elizabeth D Ballard Journal: J Psychiatr Res Date: 2022-01-15 Impact factor: 4.791
Authors: L Turgunova; Ye Laryushina; A Turmukhambetova; B Koichubekov; M Sorokina; I Korshukov Journal: Behav Neurol Date: 2017-10-25 Impact factor: 3.342
Authors: Michael E Thase; John Edwards; Suresh Durgam; Changzheng Chen; Cheng-Tao Chang; Maju Mathews; Carl P Gommoll Journal: Int Clin Psychopharmacol Date: 2017-09 Impact factor: 1.659
Authors: Barbara Stanley; Christa D Labouliere; Gregory K Brown; Kelly L Green; Hanga C Galfalvy; Molly T Finnerty; Prabu Vasan; Anni Kramer Cummings; Milton Wainberg; Jay W Carruthers; Lisa B Dixon Journal: Contemp Clin Trials Date: 2020-11-18 Impact factor: 2.226